Using a novel class of highly selective HDAC inhibitors and genetically deficient mouse models, the foregoing study revealed that HDAC11 was necessary for oncogenic JAK2-driven myeloproliferative neoplasm cell and tissue proliferation and survival (Yue et al., 2020). This evidence concerns the gene HDAC11 and myeloproliferative neoplasm.